Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
-
COVID-19 variant vaccine trial began at KPWHRI
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
-
NIH clinical trial evaluating Moderna COVID-19 variant vaccine began
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
-
Measles vaccine used as base for experimental COVID vaccine
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
-
Qx Therapeutics received FDA authorization with IND for QXT-101 in phase 2 trial for patients with COVID-19 infection.
On Mar. 30, 2021, Qx Therapeutics announced that the FDA had cleared the companyﾒs Investigational New Drug application…
-
Humanigen reported positive phase 3 results demonstrating Lenzilumabﾙ improved survival without mechanical ventilation with COVID-19
On Mar. 29, 2021, Humanigen announced positive topline results from its Phase 3 clinical trial evaluating the efficacy…
-
Clover Biopharma and Dynavax announcd first participants dosed in phase 2/3 trial for COVID-19 vaccine candidate
On Mar. 24, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have were dosed in Clover’s…
-
Investigational AstraZeneca vaccine prevented COVID-19
On Mar. 22, 2021, the NIH announced that results from a large clinical trial in the U.S. and…
-
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
-
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
-
NIH launched last phase 3 clinical trial to evaluate safety and effectiveness of blood thinners in adults with COVID-19
On Mar. 8, 2021, the NIH announced that it had launched the last of three phase 3 clinical…
-
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
-
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
-
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the National Institutes of Health (NIH) announced that the ACTIV-3 clinical trial evaluating the…
-
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the National Institutes of Health (NIH) halted a clinical trial evaluating the safety and…
-
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
-
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
-
Altimmune commenced enrollment in phase 1 trial of AdCOVID needle-free, single-dose Intranasal COVID-19 vaccine candidate
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
-
NeuroRx announced that ZYESAMI (Aviptadil) had successfully demonstrated accelerated recovery from Covid-19 respiratory failure
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
-
Monoclonal antibodies against MERS Coronavirus showed promise in phase 1 NIH-sponsored trial
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
-
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
-
Johnson & Johnson announces submission to WHO for EUL of investigational single-shot COVID-19 vaccine candidate
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
-
World’s largest clinical trial for COVID-19 treatments expanded internationally
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
-
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
-
Plans underway for pediatric COVID-19 vaccine trials
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
-
Altimmune announced FDA clearance of AdCOVID IND application
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
-
Anixa Biosciences began animal Testing of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
-
Johnson & Johnson announced submission of Marketing Authorisation Application to EMA for Janssen COVID-19 vaccine candidate
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
-
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
